Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance

This study will have 2 arms and patients will be randomized 2:1 into the Proscavax treatment arm (Arm 1) versus the active surveillance arm (Arm 2). In study Arm 1, 6 doses of the vaccine will be administered intradermally at weeks 1, 2, 3, 7, 11, and 15, followed by maintenance booster injections once every month which will alternate between low dose IL‐2 alone (at weeks 19, 27 and 35) and Proscavax vaccine (at weeks 23, 31, 39) for 6 months. In study Arm 2, patients will undergo active surveillance and will not receive any Proscavax vaccine treatment.